Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:15:36.107Z.
Calculation as of: 2026-10-06T14:15:36.107Z.
Quote observation: 2026-10-06T14:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d554412806125b06490580232e6d80b3120c6a72214b764814008bb1d876b03
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Ainos, Inc.
Market Cap
$9.76M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Ainos, Inc. (AIMD) | $9.76M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.48M | N/A |
| MetaVia Inc. (MTVA)vs › | $10.03M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.22M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.27M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.04M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.66M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.55M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.55M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.75M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
